• About us
• Contact

Advertisement

Organisation › Details

Boehringer Ingelheim Vetmedica Inc. (BIVI)

Boehringer Ingelheim Vetmedica Inc. (BIVI), is the U.S. animal health division of Boehringer Ingelheim GmbH. BIVI develops, manufactures and markets novel and innovative solutions for the prevention and treatment of disease in the cattle, equine, pet and swine markets. BIVI is the fifth largest animal health company in the U.S. The company has 2,000 employees unleashing their collective passion to keep animals healthy every day. With more than 3,800 employees worldwide, Boehringer Ingelheim Animal Health achieved net sales of about 1.4 billion euros in 2015. In its research-driven Animal Health business, Boehringer Ingelheim continually invests more than 11 percent of net sales of the Animal Health business in R&D. Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally through 145 affiliates and a total of some 47,500 employees. Founded in 1885, the focus of the family-owned company is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. *

 

	Start	2012-01-07 existent
	Group	Boehringer Ingelheim (Group)
	Predecessor	Boehringer Ingelheim Animal Health Inc.
	Industry	DRUGS, VETERINARY
	Industry 2	animal health
	Street	2621 North Belt Highway
	City	64506-2002 St. Joseph, MI
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2023-07-10

Advertisement

More documents for Boehringer Ingelheim (Group)

• [1] Boehringer Ingelheim. (4/9/24). "Press Release: Boehringer Ingelheim Biopharmaceuticals China Receives Approval for Supply of EU and US Markets". Ingelheim & Shanghai....
• [2] Boehringer Ingelheim. (1/4/24). "Press Release: Boehringer Ingelheim and 3T Biosciences Enter into a Second Partnership to Develop Next-generation Cancer Immunotherapies". Oxford....
• [3] Enara Bio Ltd.. (1/4/24). "Press Release: Boehringer Ingelheim Licenses Multiple Dark Antigens from Enara Bio to Develop Off-the-Shelf Immunotherapies for Non-small Cell Lung Cancer (NSCLC)". Oxford....
• [4] Boehringer Ingelheim. (1/3/24). "Press Release: Boehringer Ingelheim Partners with Ribo to Develop New Treatments for People with Liver Diseases". Ingelheim, Mölndal & Kunshan....
• [5] AC Immune S.A.. (12/15/23). "Press Release: AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO". Lausanne....
• [6] Boehringer Ingelheim. (11/28/23). "Press Release: Boehringer Ingelheim and IBM Collaborate to Advance Generative AI and Foundation Models for Therapeutic Antibody Development". Ingelheim & Armonk, NY....
• [7] Boehringer Ingelheim. (11/22/23). "Press Release: Boehringer Ingelheim Expands Immuno-oncology Portfolio with the Acquisition of Bacterial Cancer Therapy Specialist T3 Pharma". Ingelheim & Basel....
• [8] Glox Therapeutics Ltd.. (11/14/23). "Press Release: Glox Therapeutics Secures £4.3M Seed Funding to Develop Precision Antimicrobials Targeting Drug-resistant Bacteria". Glasgow....
• [9] Burning Rock Biotech Ltd.. (10/31/23). "Press Release: Burning Rock and Boehringer Ingelheim Achieved a Master Service Agreement in Oncology Companion Diagnostics"....
• [10] Boehringer Ingelheim. (10/2/23). "Press Release: Boehringer Ingelheim and Zeiss Join Forces to Early Detect Eye Diseases and Prevent Vision Loss". Ingelheim & Jena....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.